Phase II trial of intermediate dose methotrexate in combination with vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma (Q74635575)

From Wikidata

Jump to navigation Jump to search

scientific article published on 01 March 1999

Language	Label	Description	Also known as
English	Phase II trial of intermediate dose methotrexate in combination with vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma	scientific article published on 01 March 1999

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10091800 AND SRC:MED&resulttype=core&format=json

12 November 2019

Phase II trial of intermediate dose methotrexate in combination with vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10091800 AND SRC:MED&resulttype=core&format=json

12 November 2019

phase II clinical trial

1 reference

based on heuristic

inferred from title

transitional cell carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

P M Dodd

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10091800 AND SRC:MED&resulttype=core&format=json

12 November 2019

J A McCaffrey

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10091800 AND SRC:MED&resulttype=core&format=json

12 November 2019

M Mazumdar

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10091800 AND SRC:MED&resulttype=core&format=json

12 November 2019

H Scher

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10091800 AND SRC:MED&resulttype=core&format=json

12 November 2019

V Vlamis

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10091800 AND SRC:MED&resulttype=core&format=json

12 November 2019

G Higgins

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10091800 AND SRC:MED&resulttype=core&format=json

12 November 2019

H Herr

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10091800 AND SRC:MED&resulttype=core&format=json

12 November 2019

D F Bajorin

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10091800 AND SRC:MED&resulttype=core&format=json

12 November 2019

publication date

1 March 1999

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10091800 AND SRC:MED&resulttype=core&format=json

12 November 2019

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10091800 AND SRC:MED&resulttype=core&format=json

12 November 2019

85

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10091800 AND SRC:MED&resulttype=core&format=json

12 November 2019

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10091800 AND SRC:MED&resulttype=core&format=json

12 November 2019

1145-1150

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10091800 AND SRC:MED&resulttype=core&format=json

12 November 2019

Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-0142(19990301)85:5<1145::AID-CNCR19>3.0.CO;2-G

21 January 2018

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-0142(19990301)85:5<1145::AID-CNCR19>3.0.CO;2-G

21 January 2018

A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-0142(19990301)85:5<1145::AID-CNCR19>3.0.CO;2-G

21 January 2018

Escalated therapy for refractory urothelial tumors: methotrexate-vinblastine-doxorubicin-cisplatin plus unglycosylated recombinant human granulocyte-macrophage colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-0142(19990301)85:5<1145::AID-CNCR19>3.0.CO;2-G

21 January 2018

Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-0142(19990301)85:5<1145::AID-CNCR19>3.0.CO;2-G

21 January 2018

Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-0142(19990301)85:5<1145::AID-CNCR19>3.0.CO;2-G

21 January 2018

Escalated M-VAC chemotherapy and recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) in patients with advanced urothelial tract tumors

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-0142(19990301)85:5<1145::AID-CNCR19>3.0.CO;2-G

21 January 2018

A phase II study of methotrexate, vinblastine, doxorubicin and cisplatin plus recombinant human granulocyte-macrophage colony stimulating factors in patients with advanced transitional cell carcinoma.

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-0142(19990301)85:5<1145::AID-CNCR19>3.0.CO;2-G

21 January 2018

Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trial

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-0142(19990301)85:5<1145::AID-CNCR19>3.0.CO;2-G

21 January 2018

Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-0142(19990301)85:5<1145::AID-CNCR19>3.0.CO;2-G

21 January 2018

Treatment of invasive bladder cancer by local resection and high dose methotrexate

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-0142(19990301)85:5<1145::AID-CNCR19>3.0.CO;2-G

21 January 2018

Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-0142(19990301)85:5<1145::AID-CNCR19>3.0.CO;2-G

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-0142(19990301)85:5<1145::AID-CNCR19>3.0.CO;2-G

21 January 2018

Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-0142(19990301)85:5<1145::AID-CNCR19>3.0.CO;2-G

21 January 2018

Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

https://api.crossref.org/works/10.1002/(SICI)1097-0142(19990301)85:5<1145::AID-CNCR19>3.0.CO;2-G

21 January 2018

Identifiers

10.1002/(SICI)1097-0142(19990301)85:5<1145::AID-CNCR19>3.0.CO;2-G

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10091800 AND SRC:MED&resulttype=core&format=json

12 November 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10091800 AND SRC:MED&resulttype=core&format=json

12 November 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q74635575&oldid=2220525526"